in order to evaluate whether the hypoglycaemic action of glibenclamide during chronic treatment of obese subjects with niddm is primarily due to changes in the daytime insulin level , in insulin secretion or to changes in tissue sensitivity to insulin , we studied eight nidd 's ( age 43 +/- 3 years , body mass index 31.4 +/- 2.6 kg/m2 ) inappropriately controlled by dietary treatment alone .
C0017628
glibenclamide
C0011860
niddm